Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102-02 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules.

Late-Breaker Presentation Details Presentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal ...

Avista Therapeutics' mission is to develop innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on patients' quality of life. We ...

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical ...

Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment. Candel Therapeutics, Inc. announced the acceptance of an ...

A third oral presentation will be made by founder and Chief Technology Officer, Nick Goeden, PhD, entitled “Identification of Multiple Novel Blood-Brain-Barrier Receptors for CNS Gene Therapy and ...

Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO ...

will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...